Department of Biology, American University of Beirut, Beirut 1107 2020, Lebanon.
World J Gastroenterol. 2022 Jul 7;28(25):2867-2880. doi: 10.3748/wjg.v28.i25.2867.
Despite the significant progress in cancer therapy, colorectal cancer (CRC) remains one of the most fatal malignancies worldwide. Chemotherapy is currently the mainstay therapeutic modality adopted for CRC treatment. However, the long-term effectiveness of chemotherapeutic drugs has been hampered by their low bioavailability, non-selective tumor targeting mechanisms, non-specific biodistribution associated with low drug concentrations at the tumor site and undesirable side effects. Over the last decade, there has been increasing interest in using nanotechnology-based drug delivery systems to circumvent these limitations. Various nanoparticles have been developed for delivering chemotherapeutic drugs among which polymeric micelles are attractive candidates. Polymeric micelles are biocompatible nanocarriers that can bypass the biological barriers and preferentially accumulate in tumors the enhanced permeability and retention effect. They can be easily engineered with stimuli-responsive and tumor targeting moieties to further ensure their selective uptake by cancer cells and controlled drug release at the desirable tumor site. They have been shown to effectively improve the pharmacokinetic properties of chemotherapeutic drugs and enhance their safety profile and anticancer efficacy in different types of cancer. Given that combination therapy is the new strategy implemented in cancer therapy, polymeric micelles are suitable for multidrug delivery and allow drugs to act concurrently at the action site to achieve synergistic therapeutic outcomes. They also allow the delivery of anticancer genetic material along with chemotherapy drugs offering a novel approach for CRC therapy. Here, we highlight the properties of polymeric micelles that make them promising drug delivery systems for CRC treatment. We also review their application in CRC chemotherapy and gene therapy as well as in combination cancer chemotherapy.
尽管癌症治疗取得了重大进展,但结直肠癌(CRC)仍然是全球最致命的恶性肿瘤之一。化疗是目前 CRC 治疗的主要治疗方式。然而,化疗药物的长期疗效受到其生物利用度低、非选择性肿瘤靶向机制、非特异性生物分布以及药物在肿瘤部位浓度低和不良副作用的限制。在过去的十年中,人们越来越关注使用基于纳米技术的药物输送系统来克服这些限制。已经开发了各种用于输送化疗药物的纳米颗粒,其中聚合物胶束是有吸引力的候选物。聚合物胶束是生物相容的纳米载体,可绕过生物屏障并优先积聚在肿瘤部位——增强的通透性和保留效应。它们可以很容易地用刺激响应和肿瘤靶向部分进行工程化,以进一步确保它们被癌细胞选择性摄取,并在理想的肿瘤部位控制药物释放。它们已被证明可以有效改善化疗药物的药代动力学特性,提高其安全性和在不同类型癌症中的抗癌疗效。鉴于联合治疗是癌症治疗中采用的新策略,聚合物胶束适合多药物输送,并允许药物在作用部位同时发挥作用,以实现协同治疗效果。它们还允许与化疗药物一起输送抗癌遗传物质,为 CRC 治疗提供了一种新方法。在这里,我们强调了聚合物胶束的特性,使其成为 CRC 治疗有前途的药物输送系统。我们还回顾了它们在 CRC 化疗和基因治疗以及联合癌症化疗中的应用。